Daniel Patrick O’day Sells 10,000 Shares of Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total value of $1,193,900.00. Following the transaction, the chief executive officer directly owned 581,203 shares in the company, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Daniel Patrick O’day also recently made the following trade(s):

• On Monday, September 29th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $111.66, for a total value of $1,116,600.00.
• On Thursday, August 28th, Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00.

Gilead Sciences Trading Down 0.1%

GILD opened at $118.44 on Friday. The firm has a market cap of $146.96 billion, a price-to-earnings ratio of 23.59, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $124.61. The business’s 50 day moving average is $115.56 and its two-hundred day moving average is $111.48. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. The company had revenue of $7.77 billion for the quarter, compared to analyst estimates of $7.42 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm’s revenue was up 3.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.02 earnings per share. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, research analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Institutional Trading of Gilead Sciences

Hedge funds have recently modified their holdings of the business. Smallwood Wealth Investment Management LLC acquired a new stake in shares of Gilead Sciences in the 1st quarter valued at approximately $25,000. GoalVest Advisory LLC increased its stake in Gilead Sciences by 7,566.7% in the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Corundum Trust Company INC purchased a new position in Gilead Sciences in the 3rd quarter valued at approximately $26,000. Activest Wealth Management increased its stake in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. Finally, Harbor Asset Planning Inc. purchased a new position in Gilead Sciences in the 2nd quarter valued at approximately $27,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on GILD. Daiwa Capital Markets raised Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a research report on Tuesday, August 19th. Royal Bank Of Canada increased their price objective on Gilead Sciences from $98.00 to $100.00 and gave the stock a “sector perform” rating in a research report on Wednesday, October 8th. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. BMO Capital Markets increased their price objective on Gilead Sciences from $130.00 to $135.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. Finally, Wolfe Research increased their price objective on Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday, October 23rd. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.61.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.